136 related articles for article (PubMed ID: 18166925)
1. [Fotemustine: muphoran].
Avril MF
Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
[No Abstract] [Full Text] [Related]
2. Fotemustine for the treatment of melanoma.
Quéreux G; Dréno B
Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
[TBL] [Abstract][Full Text] [Related]
3. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
4. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Pontes L; Lopes M; Ribeiro M; Santos JG; Azevedo MC
Melanoma Res; 1997 Oct; 7(5):417-9. PubMed ID: 9429225
[TBL] [Abstract][Full Text] [Related]
6. Neurological toxicity during metastatic melanoma treatment with fotemustine.
Khalil Z; Pageot N; Carlander B; Guillot B
Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
[TBL] [Abstract][Full Text] [Related]
7. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Gill S; Shapiro J; Westerman D; Prince HM
J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
[No Abstract] [Full Text] [Related]
9. [New toxicity of fotemustine: diffuse interstitial lung disease].
Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
[TBL] [Abstract][Full Text] [Related]
10. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
11. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
12. Persistent thrombocytopenia during melanoma treatment with fotemustine.
Turrisi G; Sozzi P; Marinozzi C; Clerico MA
Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
Calabresi F; Aapro M; Becquart D; Dirix L; Wils J; Ardizzoni A; Gerard B
Ann Oncol; 1991 May; 2(5):377-8. PubMed ID: 1954183
[No Abstract] [Full Text] [Related]
14. Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Mohr P; Makki A; Breitbart E; Schadendorf D
Melanoma Res; 1998 Apr; 8(2):166-9. PubMed ID: 9610871
[TBL] [Abstract][Full Text] [Related]
15. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
Leyvraz S; Piperno-Neumann S; Suciu S; Baurain JF; Zdzienicki M; Testori A; Marshall E; Scheulen M; Jouary T; Negrier S; Vermorken JB; Kaempgen E; Durando X; Schadendorf D; Gurunath RK; Keilholz U
Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
[No Abstract] [Full Text] [Related]
17. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment and other combination regimens.
Bajetta E; Del Vecchio M; Bajetta R; Canova S
Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
[No Abstract] [Full Text] [Related]
19. Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment.
Webster GJ; Kurtovic J; Singh-Grewal I; Friedlander M; Riordan SM
Intern Med J; 2004 May; 34(5):298-9. PubMed ID: 15151681
[No Abstract] [Full Text] [Related]
20. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
Terheyden P; Becker JC; Kämpgen E; Bröcker EB
Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
